1. Home
  2. GMM vs ACET Comparison

GMM vs ACET Comparison

Compare GMM & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Mofy Metaverse Limited

GMM

Global Mofy Metaverse Limited

HOLD

Current Price

$1.34

Market Cap

38.4M

Sector

N/A

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.53

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMM
ACET
Founded
2017
1947
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
93.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
GMM
ACET
Price
$1.34
$0.53
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
15.8K
1.9M
Earning Date
08-18-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.79
N/A
Revenue
$48,171,048.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.75
N/A
Revenue Growth
41.74
N/A
52 Week Low
$1.23
$0.45
52 Week High
$4.97
$1.12

Technical Indicators

Market Signals
Indicator
GMM
ACET
Relative Strength Index (RSI) 30.01 33.71
Support Level $1.25 $0.53
Resistance Level $1.59 $0.57
Average True Range (ATR) 0.09 0.05
MACD -0.02 0.00
Stochastic Oscillator 28.21 5.35

Price Performance

Historical Comparison
GMM
ACET

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: